林奇综合征患者胃癌与十二指肠癌的发病率及内镜监测:系统评价与荟萃分析
该系统评价与荟萃分析纳入35项研究、33530例林奇综合征患者,汇总每1000人年胃癌发病率为0.98、十二指肠癌为1.93,发病率随错配修复基因不同而异;探索性比较分析显示食管胃十二指肠镜监测与观察到的胃癌风险降低相关,但与十二指肠癌风险无显著差异,现有比较证据有限且为观察性。
要点
- 林奇综合征患者胃癌汇总发病率为0.98/1000人年,十二指肠癌为1.93/1000人年。
- 胃癌发病率因错配修复基因而异:MLH1为0.44、MSH2为1.27、MSH6为0.03。
- 食管胃十二指肠镜监测与观察到的胃癌风险降低相关,但证据有限且为观察性。
核心结论
- 林奇综合征与临床相关的胃癌和十二指肠癌发病率相关,风险随错配修复基因不同而异。
- 当前食管胃十二指肠镜监测的比较证据有限且为观察性,不能确立癌症发病率降低或生存获益。
- 研究结果支持进一步评估风险适应的上消化道内镜监测。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、Embase和Scopus至2026年1月。
- 纳入报告基因确诊林奇综合征患者胃癌或十二指肠癌发病率、或比较有无食管胃十二指肠镜监测的队列研究和临床试验。
- 共分析35项研究,包括33530例林奇综合征患者。
主要发现
- 胃癌汇总发病率为每1000人年0.98(95%CI 0.54-1.42),十二指肠癌为每1000人年1.93(95%CI 0.71-3.15)。
- 胃癌发病率:MLH1为0.44、MSH2为1.27、MSH6为0.03。
- 十二指肠癌发病率:MLH1为0.95、MSH2为0.46。
- 基于每项结局2项观察性研究的探索性比较分析中,食管胃十二指肠镜监测与观察到的胃癌风险降低相关(风险比0.31;95%CI 0.14-0.69)。
- 食管胃十二指肠镜监测与观察到的十二指肠癌风险无显著差异(风险比0.78;95%CI 0.35-1.74)。
临床怎么用
- 临床应关注林奇综合征患者上消化道肿瘤风险,并按错配修复基因评估风险差异。
- 食管胃十二指肠镜监测对胃癌的潜在获益仅为观察性证据,需个体化决策。
- 不宜基于现有证据确立常规上消化道内镜监测可降低癌症发病率或改善生存。
局限性
- 食管胃十二指肠镜监测的比较证据有限,仅基于每项结局2项观察性研究。
- 研究为观察性设计,不能确立监测与癌症发病率降低或生存获益的因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Lynch syndrome is associated with gastric cancer and duodenal cancer, but risk estimates and the role of upper endoscopy surveillance remain uncertain. METHODS: We searched PubMed, Embase, and Scopus through January 2026. Cohort studies and clinical trials reporting gastric cancer or duodenal cancer incidence in genetically confirmed Lynch syndrome, or comparing patients with and without esophagogastroduodenoscopy surveillance, were included. Incidence rates per 1000 person-years were pooled overall and by mismatch repair gene. When available, risk ratios compared esophagogastroduodenoscopy surveillance with no surveillance. RESULTS: In total, 35 studies including 33,530 patients with Lynch syndrome were analyzed. The pooled incidence rate per 1000 person-years was 0.98 (95% confidence interval, 0.54-1.42) for gastric cancer and 1.93 (95% confidence interval, 0.71-3.15) for duodenal cancer. The incidence rates of gastric cancer were 0.44 for MLH1, 1.27 for MSH2, and 0.03 for MSH6. The incidence rates of duodenal cancer were 0.95 for MLH1 and 0.46 for MSH2. In exploratory comparative analyses based on 2 observational studies per outcome, esophagogastroduodenoscopy surveillance was associated with a lower observed gastric cancer risk (risk ratio, 0.31; 95% confidence interval, 0.14-0.69) but not with a different observed duodenal cancer risk (risk ratio, 0.78; 95% confidence interval, 0.35-1.74). CONCLUSIONS: Lynch syndrome is associated with clinically relevant gastric cancer and duodenal cancer incidence, with risk varying by mismatch repair gene. Current comparative evidence for esophagogastroduodenoscopy surveillance is limited and observational. These findings support further evaluation of risk-adapted upper endoscopic surveillance but do not establish reduced cancer incidence or a survival benefit.
引用
- Ausina-Poüs V, Baile-Maxía S, Sáez-Rico M, et al. Gastric and Duodenal Cancers in Lynch Syndrome: Incidence and Endoscopic Surveillance-A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2026. PMID: 42790840. doi:10.1016/j.cgh.2026.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。